Request for Information Inviting Input on an NIH-Wide Strategic Plan for Autoimmune Disease Research, 2626-2627 [2024-00695]

Download as PDF 2626 Federal Register / Vol. 89, No. 10 / Tuesday, January 16, 2024 / Notices on Deafness and Other Communication Disorders, National Institutes of Health, 6001 Executive Boulevard, Room 8351, Bethesda, MD 20892, (301) 451–6339, kellya2@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.173, Biological Research Related to Deafness and Communicative Disorders, National Institutes of Health, HHS) DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Deafness and Other Communication Disorders; Notice of Closed Meetings ddrumheller on DSK120RN23PROD with NOTICES1 Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Deafness and Other Communication Disorders Special Emphasis Panel; NIDCD Chemosensory Fellowship Application Review 2. Date: February 8, 2024. Time: 2:00 p.m. to 3:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852. Contact Person: Shiguang Yang, DVM, Ph.D., Scientific Review Officer, Division of Extramural Activities, NIDCD, NIH, 6001 Executive Blvd., Room 8349, Bethesda, MD 20892, 301–496–8683, yangshi@ nidcd.nih.gov. Name of Committee: National Institute on Deafness and Other Communication Disorders Special Emphasis Panel; NIDCD Clinical Research Center Grant Review. Date: March 12, 2024. Time: 2:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852. Contact Person: Andrea B. Kelly, Ph.D., Scientific Review Officer, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, 6001 Executive Boulevard, Room 8351, Bethesda, MD 20892, (301) 451–6339, kellya2@nih.gov. Name of Committee: National Institute on Deafness and Other Communication Disorders Special Emphasis Panel; NIDCD Clinician-Scientist Training Review. Date: March 21, 2024. Time: 1:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852. Contact Person: Andrea B. Kelly, Ph.D., Scientific Review Officer, National Institute VerDate Sep<11>2014 18:57 Jan 12, 2024 Jkt 262001 Dated: January 9, 2024. Victoria E. Townsend, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–00632 Filed 1–12–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Center for Complementary & Integrative Health; Notice of Closed Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Center for Complementary and Integrative Health Special Emphasis Panel; Research Network to Promote Multidisciplinary Mechanistic and Translational Studies of Sickle Cell Disease Pain (U24, Clinical Trial Optional). Date: February 14, 2024. Time: 12:00 p.m. to 4:00 p.m. Agenda: To review and evaluate cooperative agreement applications. Place: National Center for Complementary and Integrative Health, Democracy II, 6707 Democracy Blvd., Bethesda, MD 20892. Contact Person: Marta V. Hamity, Ph.D., Scientific Review Officer, Office of Scientific Review, Division of Extramural Activities, NCCIH/NIH, 6707 Democracy Boulevard, Suite 401, Bethesda, MD 20892, marta.hamity@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.213, Research and Training in Complementary and Alternative Medicine, National Institutes of Health, HHS) Dated: January 9, 2024. Victoria E. Townsend, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–00634 Filed 1–12–24; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Aging; Notice of Closed Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Aging Special Emphasis Panel; Brain Cell Atlas of AD/ADRD. Date: February 12, 2024. Time: 11:00 a.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Sandhya Sanghi, Ph.D., Scientific Research Officer, 7201 Wisconsin Avenue (2N230), NIA/SRB, Bethesda, MD 20814, (301) 496–2879, sandhya.sanghi@ nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS) Dated: January 10, 2024. Miguelina Perez, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–00665 Filed 1–12–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Request for Information Inviting Input on an NIH-Wide Strategic Plan for Autoimmune Disease Research AGENCY: National Institutes of Health, HHS. ACTION: Request for information. The purpose of this Request for Information (RFI) is to invite input on the development of a National Institutes of Health (NIH)-wide strategic plan to advance autoimmune disease research. NIH is seeking input from members of the scientific community, SUMMARY: E:\FR\FM\16JAN1.SGM 16JAN1 Federal Register / Vol. 89, No. 10 / Tuesday, January 16, 2024 / Notices Federal partners, academic institutions, the private sector, health professionals, professional societies, advocacy groups, patient communities, and other interested members of the public. DATES: The NIH-wide Strategic Plan for Autoimmune Disease Research Request for Information is open for public comment through March 1, 2024. Comments must be received by March 1, 2024, to ensure consideration. Comments received after the public comment period has closed may be considered by the Office of Autoimmune Disease Research within the Office of Research on Women’s Health. Submissions must be submitted electronically via the following website: https://rfi.grants.nih. gov/?s=656f78c997c67a6239036b22. FOR FURTHER INFORMATION CONTACT: Questions about this request for information should be directed to Vicki Shanmugam, MBBS, MRCP, FACR, CCD, Director, Office of Autoimmune Disease Research, Office of Research on Women’s Health, 6707 Democracy Boulevard, Bethesda, MD 20892, oadrorwh#rfi@od.nih.gov, 301–402–1770. SUPPLEMENTARY INFORMATION: This notice is in accordance with the 21st Century Cures Act, wherein NIH and its institutes are required to regularly update their strategic plans. In 2022, the National Academies of Sciences, Engineering, and Medicine report, Enhancing NIH Research on Autoimmune Diseasehttps://pubmed. ncbi.nlm.nih.gov/35593778/%22%20/ l%20%22:∼:text=Enhancing%20NIH %20Research%20on%20Autoimmune %20Disease%20also%20calls,years%29 %20to%20study%20disease%20across %20the%20life%20course, examined NIH research efforts related to autoimmune diseases. Subsequently, Congress, via the Joint Explanatory Statement https://www.appropriations. senate.gov/imo/media/doc/Division %20H%20-%20LHHS%20Statement %20FY23.pdf accompanying the Fiscal Year 2023 Consolidated Appropriations Act, 2023 directed the establishment of an Office of Autoimmune Disease Researchhttps://orwh.od.nih.gov/oadrorwh within the Office of Research on Women’s Health (OADR–ORWH) https://orwh.od.nih.gov/ and directed OADR–ORWH to: • Coordinate development of a multiinstitute and center (IC) strategic research plan; • Identify emerging areas of innovation and research opportunity; • Coordinate and foster collaborative research across ICs; ddrumheller on DSK120RN23PROD with NOTICES1 ADDRESSES: VerDate Sep<11>2014 18:57 Jan 12, 2024 Jkt 262001 • Annually evaluate the NIH autoimmune disease research portfolio; • Provide resources to support planning, collaboration, and innovation; and • Develop a publicly accessible central repository for autoimmune disease research. Currently, various NIH institutes, centers, and offices (ICOs) support autoimmune disease research in alignment with their individual mission areas. Establishing an NIH-wide Strategic Plan for Autoimmune Disease Research will allow OADR–ORWH to amplify ICO efforts and create opportunities for synergistic innovation focused on areas of autoimmune disease research that will benefit from multiICO partnerships and opportunities to implement cross-cutting research. Information Requested NIH is seeking input from internal and external partners throughout the scientific research, advocacy, and clinical practice communities, including those employed by NIH and by institutions receiving NIH support, as well as the public, on the following key areas related to autoimmune disease research: Objective 1: Research areas that would benefit from cross-cutting, collaborative research (these areas may include basic or translational research, clinical research, health services research, population science, data science, preventative research, biomedical engineering, and other areas of research). Objective 2: Opportunities to advance collaborative, innovative, or interdisciplinary areas of autoimmune disease research. Objective 3: Opportunities to improve outcomes for individuals living with autoimmune diseases including NIHdesignated health disparities populations https:// www.nimhd.nih.gov/about/overview/, populations and individuals with rare diseases, and specific populations that have been historically underrepresented in research and clinical trials. Objective 4: Cross-cutting areas that are integral to advancing autoimmune disease research at NIH including development of a publicly accessible central repository for autoimmune disease research, sex- and genderintentional research design across all stages of research, and engagement of all populations in research and clinical trials. Responses to this RFI are voluntary and are meant for information and planning purposes only. Do not include any proprietary, classified, confidential, PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 2627 trade secret, or sensitive information in your response. Respondents are advised that the responses are reviewed by NIH staff, and the U.S. government is under no obligation to acknowledge receipt of the information provided or provide feedback to the respondents. This RFI is for planning purposes only and should not be construed as a solicitation, grant, or cooperative agreement, or as an obligation on the part of the federal government, the NIH, or individual NIH institutes, centers, and offices to provide any kind of support for any ideas identified in response to it. The government may use the information submitted in response to this RFI at its discretion. The government reserves the right to use any submitted information on public NIH websites, in reports, in summaries of the state of the science, in any possible resultant solicitation(s), grant(s), or cooperative agreement(s), or in the development of future funding announcements. The government will not pay for the preparation of any information submitted or for the government’s use of such information. No basis for claims against the U.S. government shall arise as a result of a response to this request for information or from the government’s use of such information. NIH looks forward to your input, and we hope that you will share this RFI document with your colleagues. Dated: January 6, 2024. Lawrence A. Tabak, Principal Deputy Director, National Institutes of Health. [FR Doc. 2024–00695 Filed 1–12–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the National Institute on Drug Abuse Special Emphasis Panel, February 13, 2024, 10:00 a.m. to February 14, 2024, 05:00 p.m., National Institute of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 which was published in the Federal Register on November 24, 2023, FR Doc 2023– 25938, 88 FR 82387. This notice is being amended to change the meeting date from February 13–14, 2024 to February 14, 2024. The meeting time and location will remain E:\FR\FM\16JAN1.SGM 16JAN1

Agencies

[Federal Register Volume 89, Number 10 (Tuesday, January 16, 2024)]
[Notices]
[Pages 2626-2627]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-00695]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Request for Information Inviting Input on an NIH-Wide Strategic 
Plan for Autoimmune Disease Research

AGENCY: National Institutes of Health, HHS.

ACTION: Request for information.

-----------------------------------------------------------------------

SUMMARY: The purpose of this Request for Information (RFI) is to invite 
input on the development of a National Institutes of Health (NIH)-wide 
strategic plan to advance autoimmune disease research. NIH is seeking 
input from members of the scientific community,

[[Page 2627]]

Federal partners, academic institutions, the private sector, health 
professionals, professional societies, advocacy groups, patient 
communities, and other interested members of the public.

DATES: The NIH-wide Strategic Plan for Autoimmune Disease Research 
Request for Information is open for public comment through March 1, 
2024. Comments must be received by March 1, 2024, to ensure 
consideration. Comments received after the public comment period has 
closed may be considered by the Office of Autoimmune Disease Research 
within the Office of Research on Women's Health.

ADDRESSES: Submissions must be submitted electronically via the 
following website: https://rfi.grants.nih.gov/?s=656f78c997c67a6239036b22.

FOR FURTHER INFORMATION CONTACT: Questions about this request for 
information should be directed to Vicki Shanmugam, MBBS, MRCP, FACR, 
CCD, Director, Office of Autoimmune Disease Research, Office of 
Research on Women's Health, 6707 Democracy Boulevard, Bethesda, MD 
20892, oadr-orwh#[email protected], 301-402-1770.

SUPPLEMENTARY INFORMATION: This notice is in accordance with the 21st 
Century Cures Act, wherein NIH and its institutes are required to 
regularly update their strategic plans. In 2022, the National Academies 
of Sciences, Engineering, and Medicine report, Enhancing NIH Research 
on Autoimmune Diseasehttps://pubmed.ncbi.nlm.nih.gov/35593778/%22%20/
l%20%22:~:text=Enhancing%20NIH%20Research%20on%20Autoimmune%20Disease%20
also%20calls,years%29%20to%20study%20disease%20across%20the%20life%20cou
rse, examined NIH research efforts related to autoimmune diseases. 
Subsequently, Congress, via the Joint Explanatory Statement https://www.appropriations.senate.gov/imo/media/doc/Division%20H%20-%20LHHS%20Statement%20FY23.pdf accompanying the Fiscal Year 2023 
Consolidated Appropriations Act, 2023 directed the establishment of an 
Office of Autoimmune Disease Researchhttps://orwh.od.nih.gov/oadr-orwh 
within the Office of Research on Women's Health (OADR-ORWH) https://orwh.od.nih.gov/ and directed OADR-ORWH to:
     Coordinate development of a multi-institute and center 
(IC) strategic research plan;
     Identify emerging areas of innovation and research 
opportunity;
     Coordinate and foster collaborative research across ICs;
     Annually evaluate the NIH autoimmune disease research 
portfolio;
     Provide resources to support planning, collaboration, and 
innovation; and
     Develop a publicly accessible central repository for 
autoimmune disease research.
    Currently, various NIH institutes, centers, and offices (ICOs) 
support autoimmune disease research in alignment with their individual 
mission areas. Establishing an NIH-wide Strategic Plan for Autoimmune 
Disease Research will allow OADR-ORWH to amplify ICO efforts and create 
opportunities for synergistic innovation focused on areas of autoimmune 
disease research that will benefit from multi-ICO partnerships and 
opportunities to implement cross-cutting research.

Information Requested

    NIH is seeking input from internal and external partners throughout 
the scientific research, advocacy, and clinical practice communities, 
including those employed by NIH and by institutions receiving NIH 
support, as well as the public, on the following key areas related to 
autoimmune disease research:
    Objective 1: Research areas that would benefit from cross-cutting, 
collaborative research (these areas may include basic or translational 
research, clinical research, health services research, population 
science, data science, preventative research, biomedical engineering, 
and other areas of research).
    Objective 2: Opportunities to advance collaborative, innovative, or 
interdisciplinary areas of autoimmune disease research.
    Objective 3: Opportunities to improve outcomes for individuals 
living with autoimmune diseases including NIH-designated health 
disparities populations https://www.nimhd.nih.gov/about/overview/, 
populations and individuals with rare diseases, and specific 
populations that have been historically underrepresented in research 
and clinical trials.
    Objective 4: Cross-cutting areas that are integral to advancing 
autoimmune disease research at NIH including development of a publicly 
accessible central repository for autoimmune disease research, sex- and 
gender-intentional research design across all stages of research, and 
engagement of all populations in research and clinical trials.
    Responses to this RFI are voluntary and are meant for information 
and planning purposes only. Do not include any proprietary, classified, 
confidential, trade secret, or sensitive information in your response. 
Respondents are advised that the responses are reviewed by NIH staff, 
and the U.S. government is under no obligation to acknowledge receipt 
of the information provided or provide feedback to the respondents. 
This RFI is for planning purposes only and should not be construed as a 
solicitation, grant, or cooperative agreement, or as an obligation on 
the part of the federal government, the NIH, or individual NIH 
institutes, centers, and offices to provide any kind of support for any 
ideas identified in response to it.
    The government may use the information submitted in response to 
this RFI at its discretion. The government reserves the right to use 
any submitted information on public NIH websites, in reports, in 
summaries of the state of the science, in any possible resultant 
solicitation(s), grant(s), or cooperative agreement(s), or in the 
development of future funding announcements.
    The government will not pay for the preparation of any information 
submitted or for the government's use of such information. No basis for 
claims against the U.S. government shall arise as a result of a 
response to this request for information or from the government's use 
of such information.
    NIH looks forward to your input, and we hope that you will share 
this RFI document with your colleagues.

    Dated: January 6, 2024.
Lawrence A. Tabak,
Principal Deputy Director, National Institutes of Health.
[FR Doc. 2024-00695 Filed 1-12-24; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.